Literature DB >> 27453697

A Review of Pharmacological Management of Attention-Deficit/Hyperactivity Disorder.

Leslie Briars1, Timothy Todd2.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a common psychological diagnosis in children. This disorder impacts children and adolescents in all areas of life, including academic performance, extracurricular activities, and social interactions. ADHD can continue into adulthood where unemployment and substance abuse has been described. Although behavioral therapy is recommended for all patients with ADHD, medication management typically is initiated soon after diagnosis. Psychostimulants remain the primary medication of choice. This review focuses on the clinical use of psychostimulant medication in children and adolescents. The pharmacodynamic and pharmacokinetic differences between the newest long-acting formulations as well as commonly encountered adverse drug reactions, with suggested management strategies, will be highlighted. Non-stimulant therapy with atomoxetine or alpha2-adrenergic agonists is also reviewed. These agents may be warranted for patients who cannot tolerate psychostimulant therapy or have a comorbid condition. Finally, the 8-year multimodal treatment study results are also discussed.

Entities:  

Keywords:  adolescent; alpha2-agonist; amphetamine; atomoxetine; attention deficit disorder with hyperactivity; central nervous system stimulants; child; clonidine; methylphenidate; pediatric

Year:  2016        PMID: 27453697      PMCID: PMC4956327          DOI: 10.5863/1551-6776-21.3.192

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  40 in total

1.  ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser
Journal:  Pediatrics       Date:  2011-10-16       Impact factor: 7.124

2.  Clonidine in child and adolescent psychiatry.

Authors:  R D Hunt; L Capper; P O'Connell
Journal:  J Child Adolesc Psychopharmacol       Date:  1990       Impact factor: 2.576

Review 3.  Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children.

Authors:  Vanessa R Anderson; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.

Authors:  Samuele Cortese; Martin Holtmann; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Ralf W Dittmann; John Graham; Eric Taylor; Joseph Sergeant
Journal:  J Child Psychol Psychiatry       Date:  2013-01-07       Impact factor: 8.982

Review 5.  Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).

Authors:  Floyd R Sallee; Katherine Eaton
Journal:  Expert Opin Pharmacother       Date:  2010-10       Impact factor: 3.889

6.  A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

Authors:  W E Pelham; H R Aronoff; J K Midlam; C J Shapiro; E M Gnagy; A M Chronis; A N Onyango; G Forehand; A Nguyen; J Waxmonsky
Journal:  Pediatrics       Date:  1999-04       Impact factor: 7.124

7.  Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Authors:  Brooke S G Molina; Stephen P Hinshaw; L Eugene Arnold; James M Swanson; William E Pelham; Lily Hechtman; Betsy Hoza; Jeffery N Epstein; Timothy Wigal; Howard B Abikoff; Laurence L Greenhill; Peter S Jensen; Karen C Wells; Benedetto Vitiello; Robert D Gibbons; Andrea Howard; Patricia R Houck; Kwan Hur; Bo Lu; Sue Marcus
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-02-08       Impact factor: 8.829

Review 8.  Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Authors:  Sharon B Wigal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 9.  Attention-deficit-hyperactivity disorder: an update.

Authors:  Julie A Dopheide; Steven R Pliszka
Journal:  Pharmacotherapy       Date:  2009-06       Impact factor: 4.705

10.  National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment.

Authors: 
Journal:  Pediatrics       Date:  2004-04       Impact factor: 7.124

View more
  28 in total

1.  Knockout of latrophilin-3 in Sprague-Dawley rats causes hyperactivity, hyper-reactivity, under-response to amphetamine, and disrupted dopamine markers.

Authors:  Samantha L Regan; Jillian R Hufgard; Emily M Pitzer; Chiho Sugimoto; Yueh-Chiang Hu; Michael T Williams; Charles V Vorhees
Journal:  Neurobiol Dis       Date:  2019-06-06       Impact factor: 5.996

Review 2.  Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.

Authors:  Nada A Elsayed; Kaila M Yamamoto; Tanya E Froehlich
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

Review 3.  Pharmacotherapies for decreasing maladaptive choice in drug addiction: Targeting the behavior and the drug.

Authors:  Frank N Perkins; Kevin B Freeman
Journal:  Pharmacol Biochem Behav       Date:  2017-06-27       Impact factor: 3.533

Review 4.  Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners.

Authors:  Kelly A Brown; Sharmeen Samuel; Dilip R Patel
Journal:  Transl Pediatr       Date:  2018-01

5.  Assessment of tolerance to the effects of methamphetamine on daytime and nighttime activity evaluated with actigraphy in rhesus monkeys.

Authors:  Laís F Berro; Monica L Andersen; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-06-07       Impact factor: 4.530

6.  Exocytosis-related genes and response to methylphenidate treatment in adults with ADHD.

Authors:  B S da Silva; R B Cupertino; D L Rovaris; J B Schuch; D B Kappel; D Müller; C E Bandeira; M M Victor; R G Karam; N R Mota; L A Rohde; V Contini; E H Grevet; C H D Bau
Journal:  Mol Psychiatry       Date:  2017-05-02       Impact factor: 15.992

7.  Effects of methamphetamine on neural responses to visual stimuli.

Authors:  Kathryne Van Hedger; Sarah K Keedy; Kathryn E Schertz; Marc G Berman; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2019-01-02       Impact factor: 4.530

8.  Effects of benztropine analogs on delay discounting in rats.

Authors:  Paul L Soto; Takato Hiranita
Journal:  Psychopharmacology (Berl)       Date:  2020-09-22       Impact factor: 4.530

9.  Posterior reversible leukoencephalopathy syndrome after kratom ingestion.

Authors:  Austin Castillo; J Drew Payne; Kenneth Nugent
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-07

10.  Adult Patient Preferences for Long-Acting ADHD Treatments: A Discrete Choice Experiment.

Authors:  M Janelle Cambron-Mellott; Jaromir Mikl; Joana E Matos; Jennifer G Erensen; Kathleen Beusterien; Marc J Cataldo; Bernadette Hallissey; Gregory W Mattingly
Journal:  Patient Prefer Adherence       Date:  2021-05-21       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.